AC Immune’s Anti-Tau Vaccine ACI-35.030 to Be Tested in Phase 1b/2a Trial

AC Immune’s Anti-Tau Vaccine ACI-35.030 to Be Tested in Phase 1b/2a Trial
AC Immune is launching a Phase 1b/2a clinical trial to evaluate an investigational anti-tau vaccine called ACI-35.030 as a potential disease-modifying treatment for Alzheimer’s disease and other disorders characterized by the accumulation of tau protein. The presence of abnormal aggregates of beta-amyloid and tau proteins in the brain are two hallmarks of Alzheimer’s underlying several features of the disease, such as disrupted communication between nerve cells. Tau proteins are necessary components of healthy brain nerve cells, but in Alzheimer’s, these proteins undergoes chemical modifications — a process called hyperphosphorylation — that makes them stick together, forming a complex known as tau tangles. ACI-35.030, developed in collaboration with Janssen Pharmaceuticals, is a liposome-based vaccine consisting of a synthetic peptide antigen (a molecule capable of inducing an immune response) and a fat-made anchor. ACI-35.030 mimics the structure of the toxic tau protein to induce an anti-immune response against it. The aim is to trigger the immune system to produce antibodies that selectively target the toxic forms of this protein. The vaccine may help to prevent and reduce the spread and development of toxic forms of tau protein within the brain. In preclinical studies, ACI-35.030 showed a good safety profile and high specificity for toxic forms of ta
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *